Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma
Mehrad Adibi(The University of Texas MD Anderson Cancer Center), Matthew T. Campbell(The University of Texas MD Anderson Cancer Center), Firas G. Petros(The University of Texas MD Anderson Cancer Center), Amishi Y. Shah(The University of Texas MD Anderson Cancer Center), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Charles Guo(The University of Texas MD Anderson Cancer Center), Arlene O. Siefker‐Radtke(The University of Texas MD Anderson Cancer Center), Lianchun Xiao(The University of Texas MD Anderson Cancer Center), Jianjun Gao(Chinese General Hospital College of Nursing and Liberal Arts), Surena F. Matin(The University of Texas MD Anderson Cancer Center), Minas P. Economides(NYU Langone Health), Neema Navai(The University of Texas MD Anderson Cancer Center), Barrett Z. McCormick(The University of Texas MD Anderson Cancer Center), Colin P. Dinney(The University of Texas MD Anderson Cancer Center)
Cited by 14
Related Papers
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
|JAMA Oncology|2019|472
Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia
|Blood|2006|468
Urothelial Carcinoma of the Bladder and the Upper Tract: Disparate Twins
|The Journal of Urology|2012|359